Trials / Completed
CompletedNCT02652091
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 146 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess adherence and persistence to BETASERON therapy in patients who are using the BETACONNECT auto-injector device (BETACONNECT device). The secondary objective of this study is to assess patient-reported satisfaction with the BETACONNECT device.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon beta-1b (Betaseron, BAY86-5046) | Applied via the BETACONNECT device. Dose as prescribed by physician. |
| DEVICE | BETACONNECT device | Used to apply Betaseron. |
Timeline
- Start date
- 2016-02-05
- Primary completion
- 2017-08-11
- Completion
- 2017-09-13
- First posted
- 2016-01-11
- Last updated
- 2018-09-06
Locations
23 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02652091. Inclusion in this directory is not an endorsement.